Supplementation with complex milk lipids during brain development promotes neuroplasticity without altering myelination or vascular density

Rosamond B. Guillermo 1,2, Panzao Yang 1,2, Mark H. Vickers 1, Paul McJarrow 3 and Jian Guan 1,2*

1Liggins Institute, The University of Auckland, Auckland, New Zealand; 2Centre for Brain Research, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand; 3Fonterra Research and Development Centre, Palmerston North, New Zealand

Abstract

Background: Supplementation with complex milk lipids (CML) during postnatal brain development has been shown to improve spatial reference learning in rats.

Objective: The current study examined histo-biological changes in the brain following CML supplementation and their relationship to the observed improvements in memory.

Design: The study used the brain tissues from the rats (male Wistar, 80 days of age) after supplementing with either CML or vehicle during postnatal day 10–80. Immunohistochemical staining of synaptophysin, glutamate receptor-1, myelin basic protein, isolectin B-4, and glial fibrillary acidic protein was performed. The average area and the density of the staining and the numbers of astrocytes and capillaries were assessed and analysed.

Results: Compared with control rats, CML supplementation increased the average area of synaptophysin staining and the number of GFAP astrocytes in the CA3 sub-region of the hippocampus (p < 0.01), but not in the CA4 sub-region. The supplementation also led to an increase in dopamine output in the striatum that was related to nigral dopamine expression (p < 0.05), but did not alter glutamate receptors, myelination or vascular density.

Conclusion: CML supplementation may enhance neuroplasticity in the CA3 sub-regions of the hippocampus. The brain regions-specific increase of astrocyte may indicate a supporting role for GFAP in synaptic plasticity. CML supplementation did not associate with postnatal white matter development or vascular remodelling.

Keywords: complex milk lipids; brain development; neuroplasticity; dopamine; myelination; vascular density

To access the supplementary material to this article, please see Supplementary files under 'Article Tools'.

Received: 18 August 2014; Revised: 23 January 2015; Accepted: 3 February 2015; Published: 27 March 2015
understand the biological changes associated with the improved brain function after CML supplementation.

The hippocampus and the striatum are the brain regions that process spatial reference learning and memory (7–10). The changes in synaptic plasticity in these brain regions, for example, dopamine outputs and glutamate receptors, may be the biological modifications underlying the observed improvements in learning and memory (8, 9, 11). Synaptophysin is a marker for synaptic vesicles and has been commonly used as a marker for synaptic plasticity at pre-synaptic location (12, 13). Improved dopamine neurotransmission has been reported to be associated with improved memory in aged rats after long-term supplementation with a concentrate of dairy lipids (12). In addition to a supporting role for astrocytes in neuronal and synaptic plasticity (14), neuronal–glial–vascular networking plays an essential role in neuronal function (15) and myelination (16). Phospholipids are also important components of white matter development (17) and supplementation with lipids in early life may promote myelination (18).

The current study evaluated the effect of postnatal supplementation with CML on synaptic plasticity, myelination, astrocytes, and vascular remodelling using the brain tissue collected from a previous study that demonstrated the efficacy of CML in improved memory.

**Methods**

**Animal model**

The brain tissues that are utilised for the current study were banked from a previous experimental study undertaken in the rat, which has been described elsewhere (5).

In brief, male Wistar rats (n = 16 per group) were supplemented from postnatal day 10 until day 80 with either CML (a complex lipid ingredient enriched in gangliosides and phospholipids at 1% w/w of food intake) or gelatine formulated CML supplementation to a standard chow vehicle by oral gavage before weaning (day 21) or gelatine respectively. Either CML (a complex lipid ingredient enriched in gangliosides and phospholipids at 1% w/w of food intake) or gelatine formulated CML supplementation to a standard chow vehicle by oral gavage before weaning (day 21) or gelatine supplementation to a standard chow vehicle by oral gavage before weaning (day 21) or gelatine respectively.

The following primary antibodies were used: monoclonal mouse anti-synaptophysin for synaptic vesicles (Sigma L:1000), rabbit anti-tyrosine hydroxylase for dopamine (TH, Protos Biotech Corporation 1:250), rabbit anti-GluR-1 for glutamate receptors (Chemicon 1:100), mouse anti-myelin basic protein for myelin density (MBP, Jomar Millipore 1:1000), and mouse anti-glial fibrillary acidic protein for astrocyte (GFAP, Sigma, 1:2000). These sections were incubated with the primary antibodies for 48 h at 4°C, and then incubated with goat anti-rabbit or goat anti-mouse secondary antibody (Sigma 1:200) accordingly overnight at 4°C before being incubated with tertiary antibody (ExtrAvidin Peroxidase 1:200) for 3 h at room temperature. The staining was visualised using 3, 3-diaminobenzidine tetrahydrochloride (DAB). For visualising blood vessels, biotin-conjugated isoclectin B-4 (IB4) (Sigma 1:4000) was used (Sigma, St. Louis, MO, USA). The sections were pre-treated with 1% hydrogen peroxide in 50% methanol after being deparaffinised, and were then incubated overnight at 4°C with IB4 (1:4) in Tris-buffered saline before being developed in DAB. The sections were washed three times with PBS for 15 min between each step. Finally, the sections were washed in PBS and dehydrated in serial concentrations of ethanol and xylene before being cover-slipped with DPX.

**Image acquisition and analysis**

The methods of image acquisition and analysis have been reported previously (8, 19). Briefly, light microscopy (Nikon 800, Tokyo, Japan) and photographic software (Nikon Digital Sight) were used to acquire images. At least three images from each brain region and each of three sections were analysed using image analysis (Image J or SigmaScan Pro 5.5, SPSS) (8). The average areas and densities of synaptophysin, TH, GluR-1, and MBP staining in the hippocampus, the striatum, and the substantia nigra pars compacta (SNc) were analysed. The average number and the total length of blood vessels in the

---

**References**

Supplementation with complex milk lipids during brain development promotes

hippocampus and the striatum were also analysed (19). The numbers of GFAP-positive astrocytes in the CA3 and CA4 sub-regions of the hippocampus were counted. The area used for counting the cells was measured (SigmaScan Pro 5.5, SPSS) and was used for calculating cell density as cells/mm² (8).

**Data analysis**

The data were analysed using GraphPad Prism (v6.0). Two-way analysis of variance (ANOVA) was used for analysing the difference between the control and CML supplemented groups and different brain regions, with brain regions being treated as dependent factors. The specific changes in the brain regions were analysed using a multiple comparisons procedure (Sidak’s) where an overall difference between the groups was identified. The difference of dopamine ratios between the CML and control supplemented groups was analysed using unpaired t-tests. The correlation between synaptophysin staining and our previously published MWM data (5) was also analysed using Pearson tests. The data are presented as mean ± standard error of the mean (SEM). A p value of less than 0.05 was considered to be significant.

**Results**

**Synaptophysin**

Synaptophysin staining was densely distributed within different sub-regions of the hippocampus, particularly in the CA3 (Fig. 1A) and CA4 (Fig. 1B) sub-regions. The microscopy images were representative of synaptophysin staining in the mossy fibres of the CA3 sub-region, and the CA4 sub-region, where it was defined in the area between the dorsal and ventral horns of the dentate gyrus. We evaluated both the average area (Fig. 1C) and the average density (Fig. 1D) of the staining in the sub-regions of the hippocampus.

Two-way ANOVA showed that the average area of staining was significantly different between the two regions (F[2,81] = 84.55, p < 0.001) and between the two groups (F[1,81] = 7.95, p = 0.0076), with a moderate interaction between the brain regions and the treatment groups (F[2,81] = 4.46, p = 0.014, Fig. 1C). Post-hoc tests showed that the average area of synaptophysin staining was significantly larger in the CA3 sub-region of CML group (p < 0.01, n = 16) compared to the control group (n = 15, Fig. 1C). The increase in the average area of staining in the CA4 sub-region of the hippocampus of CML group was not significant (p = 0.07, Fig. 1C). The average density of synaptophysin staining was similar between the two groups and two brain regions (Fig. 1D).

We also analysed the correlation between the area of synaptophysin in the CA3 sub-region of the hippocampus and the distance travelled to the platform in the MWM, which was significantly shorter in the CML-supplemented group than in the control group (p < 0.05, n = 16, Supplementary Fig. 1) (5). The shorter distance travelled to the hidden platform indicates the greater ability in learning. The average area of synaptophysin staining in the CA3 sub-region was trended towards a correlation with the distance travelled to the platform in the CML group (p = 0.07, r = −0.47, Fig. 1F), but not in the control group (r = 0.18, p = 0.5, Fig. 1E).

**Tyrosine hydroxylase (TH)**

Figure 2 shows microscopy images of TH staining in the SNc (Fig. 2A) and the striatum (Fig. 2B). The majority of TH staining in the SNc was associated to the process/axons of dopamine neurons and that in the striatum was located at the terminals of the dopamine neurons. To compare the association of dopamine immunoreactivity between the SNc and the striatum, TH staining was measured in the same sections, containing both SNc and striatum.

The average density and the average area of TH staining were evaluated in the A9 region of the SNc and in the striatum of both the control group (n = 14) and the CML-supplemented group (n = 15, Fig. 2C–F). Two-way ANOVA revealed a significant difference between the two brain regions in both the average area (F[1,54] = 41.6, p < 0.0001, Fig. 2C) and the average density (F[1,54] = 41.01, p < 0.0001, Fig. 2E) of TH staining, no differences between the two groups (p = 0.3) with a moderate interaction between the brain regions and the groups (F[1,54] = 4.8, p = 0.03). To compare the relative changes, we also evaluated the striatal/nigral ratio of the TH staining. The striatal/nigral ratios of the average area and the average density were significantly increased in the CML group compared with the control group (p < 0.05, Figs. 2D and F).

**Glial fibrillary acidic protein (GFAP)**

Figure 3 shows microscopy images of GFAP-positive astrocytes in the CA3 (Fig. 3A) and CA4 (Fig. 3B) sub-regions of the hippocampus. There was no hypertrophy morphology of the GFAP-positive astrocytes in any of the brain regions across both treatment groups. The density of GFAP astrocytes was used for the comparison. Two-way ANOVA showed a significant difference between the two groups (F[1,36] = 10.6, p = 0.002, n = 7–12). There was no difference between the brain regions and no interaction between the groups and the brain regions. For the CML-supplemented group, post-hoc analysis showed a significant increase in GFAP astrocytes in the CA3 sub-region of the hippocampus (p < 0.01), but not in the CA4 sub-region (Fig. 3C).

**Glutamate receptor-1 (GluR-1)**

Neither the density nor the area of staining of GluR-1 were different between the control group and the
CML-supplemented group in any of the brain regions measured (Table 1).

**Vascular**

Neither the total length nor the total number of vessels was different between the control group and the CML-supplemented group in any of the brain regions measured (Table 1).

**Myelin basic protein**

Two-way ANOVA did not show any differences in MBP between the two treatment groups or in any of the brain regions examined (Table 1).

**Discussion**

Overall, we found that long-term supplementation with CML during early brain development moderately promoted
synaptic plasticity by showing a broader area of synaptophysin and elevated astrocytes in the hippocampus, as well as altered dopamine neuroplasticity in the striatum. CML supplementation did not alter myelination and vessel density.

Synaptophysin is an integral membrane protein of synaptic vesicles. As the expression of synaptophysin indicates non-specific changes in synaptic activity at presynaptic locations (20), it has been widely used as a marker of synaptic plasticity (21–25), including dietary-associated plasticity in the hippocampus (26). The improved synaptic plasticity after CML supplementation appeared to be more specific to the changes of the area of staining but not the density within the area. Changes in synaptophysin can often be evaluated in terms of the density and the area of reactivity (13). While changes in density reflect the vesicle activity within the area, in which synaptic activity may be reduced (12, 27). Large area of synaptophysin staining may suggest broader, perhaps new, synaptic connections. The immunoreactivity of synaptophysin has commonly been used for indicating hippocampal plasticity associated with MWM performance (13, 26). We have previously reported that CML supplementation in rats results in improved learning in the MWM and better performance in novelty recognition, compared with control rats. Although there was no correlation in the control group (Fig. 1E), the improved performance in the MWM (Supplementary Fig. 1) may be associated with broader synaptic activity (Fig. 1F).

We have recently shown that memory improvement after long-term supplementation with a different form of CML (CML concentrate) was associated with enhanced synaptophysin density in the CA3 sub-regions of aged

Fig 2. Changes in TH staining in the SNc and the striatum. Representative images showing TH (×20) staining in the A9 region of the SNc (A) and in the striatum (B) of rats. The average area of TH staining in the SNc and the striatum (C), the striatum/SNc ratio of the area of TH staining (D), the average density of TH staining in the SNc and the striatum (E), and the striatum/SNc ratio of the density of TH staining (F) of control (closed bars, n = 15–16) and CML-supplemented (open bars, n = 15–16) rats are shown. Data are presented as mean ± SEM, *p < 0.05, scale bar = 100 μm.
rats (12), in which synaptic function was reduced in the control group of aged rats (12). The increase in density could have been a result of preventing/restoring the loss of synaptic function, rather than promoting synaptogenesis. As synaptogenesis is a major part of brain development in the postnatal period, the broader synaptic activity may be the changes more specific to brain development. The changes in synaptophysin appeared to be specific to the CA3 sub-region of the hippocampus, a region that plays a critical role in the encoding of new spatial information (7). Compared to the aged rats, which have clear deficits in memory, the efficacy of nutritional intervention on young normal rats appears to be more moderate in both functional outcome and biological improvements (12). The efficacy of CML supplementation in the normal rat therefore raises the important question of treatment effects in the setting of learning deficits, such as those evidenced by foetal growth retardation, and warrants further investigation.

Complex lipids have previously been implicated in improvements in neuroplasticity (12, 28). Phosphatidylserine has been perceived to participate in the activation of genes that are required for long-term neuroplasticity (28). Gangliosides, which are bioactive ingredients in the CML supplement, have previously been suggested to enhance neuroplasticity in the CA3 hippocampal region. For example, treatment of hippocampal slices with gangliosides GM1 and GD1b improves the synaptic plasticity of pyramidal neurons in the CA3 region (29).

Apart from neurons, a large part of the TH staining in the SNc is located to neuronal dendrites and axons, which project into the striatum, in which terminal TH staining is often used for evaluating dopamine outputs (30). To compare differences between neuronal and terminal staining, we used sections that contained both regions. As the SNc used for evaluation was more anterior to the centre of the nuclei, the staining was mainly of neuronal dendrites and axons, with very few neurons.
did not see any significant difference in TH reactivity between the two groups, particularly in the striatum, despite a possible lower TH staining in the SNc of the CML-supplemented group. As terminal TH staining would be more representative of dopamine function, these data suggest that CML supplementation did not alter dopamine function.

To evaluate the potential effect on neuroplasticity in the nigral–striatal dopamine pathway, we analysed the terminal/neuronal staining ratio. The ratio values were greater than 1 in all rats, indicating that the density of TH staining was greater in the striatum than in the SNc. CML supplementation significantly increased the relative value of dopamine output over neuronal staining in both the density and the area of staining (Fig. 2). Even though these changes were not related to dopamine output, the data support the efficacy of CML in altering synaptic plasticity. Without counting the number of dopamine neurons in the SNc, the relatively lower staining in the SNc may not necessarily indicate fewer dopamine neurons, as TH is generally found to be more abundant in the neuronal terminals in the striatum than in the neuronal soma and processes in the SNc (31). We have recently reported that improvements in the memory following supplementation with CML concentrates in aged rats was mediated through prevention and/or restoration of nigral–striatal dopamine depletion (12), a pathway that plays a key role in learning and memory (11). However, there is no association between the changes in TH and the performance in the MWM (data not shown).

Astrocytes are essential for, and play a critical role in, synaptic genesis and plasticity (14, 32, 33), for example, the formation and stabilisation of synaptic connections during brain development (34). A reduction in astrocytes is associated with the loss of pre-synaptic plasticity indicated by synaptophysin (12), but not of post-synaptic density protein PSD95, a marker for post-synapses in rats with age-related cognitive decline (35). Morphologically, the astrocytes did not show any sign of hypertrophy, suggesting that the reactivation of astrocytes was not an immune response. CML supplementation elevated the density of astrocyte staining in the CA3 sub-region of the hippocampus, but not in the CA4 sub-region (Fig. 3), a brain-region-dependent effect that is similar to synaptogenesis. Thus, the elevated levels of astrocytes in the CA3 sub-region of the hippocampus may have a role in forming new synapses, therefore providing indirect evidence for improved synaptic plasticity after CML supplementation.

Even though phospholipids and gangliosides are critical components of the myelin sheath (17), supplementation with CML did not alter the degree of myelination in the brain regions involved in processing learning and memory. Similarly, supplementation during brain development did not change vascular density.

**Conclusion**

Overall, these data suggest that CML supplementation during development moderately promoted synaptic plasticity in the CA3 sub-region of the hippocampus and

---

**Table 1. Efficacy of CML supplementation on GluR-1, blood vessels, and MBP**

<table>
<thead>
<tr>
<th>Markers</th>
<th>Parameters measured</th>
<th>Regions</th>
<th>Controls (mean ± SEM)</th>
<th>CML (mean ± SEM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>GluR-1</td>
<td>Average area (pixels²)</td>
<td>Hippocampus</td>
<td>3,212 ± 96</td>
<td>3,068 ± 55</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Striatum</td>
<td>3,554 ± 27</td>
<td>3,505 ± 24</td>
</tr>
<tr>
<td></td>
<td>Average density (pixels)</td>
<td>Hippocampus</td>
<td>291,956 ± 17,566</td>
<td>307,382 ± 16,474</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Striatum</td>
<td>248,696 ± 9,185</td>
<td>229,874 ± 6,158</td>
</tr>
<tr>
<td>Vessels</td>
<td>Total length (mm)</td>
<td>Hippocampus</td>
<td>2,505 ± 203</td>
<td>2,386 ± 136</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Striatum</td>
<td>1,850 ± 202</td>
<td>1,692 ± 130</td>
</tr>
<tr>
<td></td>
<td>Total number (vessels/mm²)</td>
<td>Hippocampus</td>
<td>215 ± 13</td>
<td>216 ± 2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Striatum</td>
<td>167 ± 10</td>
<td>163 ± 4</td>
</tr>
<tr>
<td>MBP</td>
<td>Average density</td>
<td>Hippocampus</td>
<td>163 ± 1</td>
<td>161 ± 4</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Striatum</td>
<td>170 ± 2</td>
<td>171 ± 4</td>
</tr>
</tbody>
</table>
altered nigral–striatal dopamine pathway in young normal rats. CML supplementation did not alter white matter development or vascular remodelling.

Author contributions
Conceived and designed the experiments: RG. Performed the experiments: RG. Analysed the data: JG PY. Wrote the paper: RG JG PM MV.

Conflicts of interest and funding
Dr. Paul McJarrow is a Fonterra employee. Financial support provided by Fonterra and the New Zealand Ministry for Primary Industries via the Dairy Primary Growth Partnership Post Farm Gate Programme.

References
13. Haley GE, Kohama SG, Urbanski HF, Raber J. Age-related decreases in SYN levels associated with increases in MAP-2, apoE, and GFAP levels in the rhesus macaque prefrontal cortex and hippocampus. Age 2010; 32: 283–96.


*Jian Guan
Liggins Institute
The University of Auckland
Private Bag 92019, Victoria Street West
Auckland 1142, New Zealand
Email: j.guan@auckland.ac.nz